The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Feb. 05, 2015
Applicant:

Baylor College of Medicine, Houston, TX (US);

Inventors:

Qizhi Yao, Houston, TX (US);

Christian Marin-Muller, League City, TX (US);

Changyi Chen, Houston, TX (US);

Assignee:

Baylor College of Medicine, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); A61K 51/00 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61K 51/00 (2013.01); A61N 5/10 (2013.01); A61K 2300/00 (2013.01); C12N 2310/141 (2013.01); Y10S 977/704 (2013.01); Y10T 428/13 (2015.01);
Abstract

A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.


Find Patent Forward Citations

Quick Actions:

Yao, Qizhi. (2017). Microrna-198 as a tumor suppressor in ovarian cancer (U.S. Patent No. 9546365). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9546365

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…